Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 7, pp 1089–1091 | Cite as

Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin

  • Elisa Maria Fiorelli
  • Roberta Elisa Rossi
  • GrAM (Gruppo di Autoformazione Metodologica)
THE CUTTING EDGE: RESEARCH UPDATE

Background

Cancer is a well-known risk factor for venous thromboembolism (VTE), both due to the presence of cancer and to cancer-related interventions. Evidence on what is the best anticoagulation strategy in cancer-associated VTE both in the acute phase and long term is limited. Guidelines recommend treatment with low-molecular-weight-heparin (LMWH) basing the evidence mainly on a single trial that shows that dalteparin is more effective than oral anticoagulation with vitamin K antagonists (VKA) in reducing VTE recurrence with a comparable risk of bleeding [1]. A Cochrane systematic review published in 2014 confirms a reduction of recurrent VTE in patients treated with LMWH compared to VKA (hazard ratio [HR] 0.47; 95% confidence interval [CI] 0.32–0.71, moderate quality of evidence) with no difference in survival and bleeding [2]. A more recent trial comparing full-dose tinzaparin with warfarin for 6 months shows that treatment with full-dose tinzaparin is not associated with a...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with humans and animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Lee A, Levine M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. Nejm 349:146–153CrossRefPubMedGoogle Scholar
  2. 2.
    Ea A, Barba M, Rohilla S et al (2014) Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer (Review). Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD006650.pub4.www.cochranelibrary.com CrossRefGoogle Scholar
  3. 3.
    Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer. JAMA 314:677.  https://doi.org/10.1001/jama.2015.9243 CrossRefPubMedGoogle Scholar
  4. 4.
    Verso M, Agnelli G, Prandoni P (2015) Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 10:651–656.  https://doi.org/10.1007/s11739-015-1233-5 CrossRefPubMedGoogle Scholar
  5. 5.
    Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615–624.  https://doi.org/10.1056/NEJMoa1711948 CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  • Elisa Maria Fiorelli
    • 1
  • Roberta Elisa Rossi
    • 2
  • GrAM (Gruppo di Autoformazione Metodologica)
  1. 1.Department of Internal MedicineFondazione IRCSS Ca’ Granda, Ospedale Maggiore PoliclinicoMilanoItaly
  2. 2.Department of Gastroenterology and Endoscopy, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico and Department of Pathophysiology and Organ TransplantUniversità degli Studi di MilanoMilanItaly

Personalised recommendations